Vertex Bet $5 Billion on a Kidney Drug. It Just Paid Off.
Vertex dropped $4.9 billion on a kidney drug most people had never heard of. Two years later, the Phase 3 data just landed, and it's turning heads across the IgA nephropathy space. The stock hit a record high.
Two years ago, Vertex Pharmaceuticals wrote a check for $4.9 billion to buy a company most people had never heard of. Alpine Immune Sciences had one drug worth talking about: povetacicept, an experimental treatment for a kidney disease that slowly destroys the organ from the inside. At the time, plenty of analysts raised an eyebrow. Vertex was a cystic fibrosis company. What was it doing spending that kind of money on kidneys?
Now we have the answer. And it's a pretty good one.
The Numbers That Moved the Stock
On March 9, Vertex dropped interim results from its Phase 3 RAINIER trial, and the data was exactly what the company needed. Povetacicept cut protein levels in patients' urine by 52% from baseline, compared to a 49.8% reduction versus placebo. Why does that matter? In IgA nephropathy (IgAN), protein leaking into urine is like a warning light on your car's dashboard. It signals that the kidneys' filters are failing. Reducing that leak is the clearest sign a drug is actually protecting the kidney.
But proteinuria (the technical term for protein in urine) wasn't the only thing that moved. The drug also slashed levels of Gd-IgA1, the rogue antibody that causes the disease, by 79.3% compared to placebo. Think of Gd-IgA1 as the arsonist: it's the molecule that triggers the immune attack on the kidneys. Knocking it down that aggressively suggests povetacicept isn't just treating symptoms; it's going after the fire itself.
Oh, and 85.1% of patients saw their blood-in-urine resolve, compared to just 23.4% on placebo. That's a clean sweep of every major endpoint the trial was designed to hit.
Vertex shares surged over 8% to a record high the next morning. Wall Street got the memo.
How Povetacicept Actually Works
IgA nephropathy is an autoimmune disease where the body's immune system gets confused and starts attacking the kidneys. Specifically, defective IgA antibodies clump together in the kidney's tiny filters, causing inflammation and scarring. Over time, about 10-30% of patients progress to complete kidney failure within 10 years, which means dialysis or a transplant.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Povetacicept works by blocking two proteins called BAFF and APRIL, which act like fuel for the immune cells producing those harmful antibodies. If the rogue antibodies are the arsonists, BAFF and APRIL are the gasoline. Cut off the supply, and the fire dies down.
The drug is a fusion protein (basically, an engineered molecule designed to intercept both targets at once) delivered as a subcutaneous injection once every four weeks. That dosing schedule matters in the competitive landscape, as we'll see in a minute.
The Safety Profile Vertex Needed
Great efficacy means nothing if the drug wrecks patients in other ways. This is where Vertex caught another break. The trial reported zero treatment-related serious adverse events and zero deaths. Dropout rates were remarkably low: just 0.8% on povetacicept versus 1.5% on placebo.
There's one caveat worth watching. Some patients developed severe hypogammaglobulinemia, which means their overall antibody levels dropped significantly. That's a predictable side effect when you're suppressing the immune machinery that makes antibodies. Severe infection rates stayed comparable to placebo, though, which is reassuring for now. The full 605-patient trial runs through Week 104, so longer-term safety data will tell a more complete story.
A Crowded Race With Real Stakes
Vertex isn't alone in chasing IgAN. The market, projected at roughly $1.5 billion and growing, has attracted a pack of competitors. Understanding who's who requires a quick scorecard.
Novartis's atrasentan already posted Phase 3 results showing a 36.1% proteinuria reduction versus placebo. But analysts at BMO flagged a potential weakness: atrasentan showed geographic variability in its results, meaning the drug worked better in some regions than others. Povetacicept's data, by contrast, was consistent across all pre-specified subgroups, including race, ethnicity, and geography. Citi's analysts pointed to this breadth of impact as a meaningful differentiator.
Vera Therapeutics' atacicept targets the same BAFF/APRIL pathway but requires weekly injections. In its Phase 3 ORIGIN trial, atacicept showed approximately a 46% proteinuria reduction at 36 weeks. Solid, but povetacicept's 49.8% placebo-adjusted reduction at just 36 weeks, with monthly dosing, gives it an edge on both speed and convenience.
Then there are already-approved options like Travere's Filspari and Novartis's Fabhalta, which have a two-year head start in clinics. First-mover advantage is real, but it can evaporate quickly when a better drug shows up.
The Road to Approval (and It's a Short One)
Vertex is moving fast. The company plans to complete its rolling BLA (biologics license application) submission to the FDA by the end of March 2026. It's also deploying a priority review voucher, which shrinks the FDA's review clock from ten months to six. If everything stays on track, povetacicept could receive accelerated approval as early as November 2026.
Accelerated approval means the FDA would green-light the drug based on proteinuria reduction as a surrogate endpoint, essentially a biomarker that's reasonably likely to predict clinical benefit. The full trial continues to Week 104 to confirm that the drug actually preserves kidney function over time (measured by eGFR slope, the gold standard for kidney outcomes). That confirmatory data will determine whether the approval sticks.
Why This Matters Beyond the Kidney
For Vertex, povetacicept represents something bigger than one drug in one disease. The company has built its empire on cystic fibrosis treatments, which generate the vast majority of its revenue. That's a fantastic franchise, but investors have long wondered: what happens when CF growth plateaus?
Povetacicept is Vertex's answer. CEO Reshma Kewalramani has called it a "pipeline-in-a-product," and she's not exaggerating. Beyond IgAN, Vertex is running a Phase 2/3 trial in primary membranous nephropathy and plans to expand povetacicept into generalized myasthenia gravis. Combined with the pain drug JOURNAVX (suzetrigine), the gene therapy CASGEVY, and a handful of earlier-stage programs, Vertex is transforming from a one-trick pony into a diversified biopharma player.
The $4.9 billion Alpine deal was a bet that Vertex could compete outside its comfort zone. With these Phase 3 results in hand and an FDA submission weeks away, that bet is looking increasingly smart.
4 min read
Immutep Lost Most of Its Value in a Single Day. Here's Why.
Immutep's stock cratered roughly 90% after an independent committee pulled the plug on its most important lung cancer trial. The failure raises tough questions about a once-promising immunotherapy approach and adds to a brutal streak of late-stage clinical disasters.
